Pallu Reddanna

Prof. Pallu Reddanna


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2010 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
BKBhusan K Kuntal
Bhusan K Kuntal
PAPolamarasetty Aparoy
Polamarasetty Aparoy
PRPallu Reddanna
Pallu Reddanna
MODELLER is a program for automated protein Homology Modeling. It is one of the most widely used tool for homology or comparative modeling of protein three-dimensional structures, but most users find it a bit difficult to start with MODELLER as it is command line based and requires knowledge of basic Python scripting to use it efficiently.

1 June 2012 in Current Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
PAPolamarasetty Aparoy
Polamarasetty Aparoy
KRKakularam Kumar Reddy
Kakularam Kumar Reddy
PRPallu Reddanna
Pallu Reddanna
Lipoxygenases (LOXs) are non-heme iron containing dioxygenases involved in the oxygenation of polyunsaturated fatty acids (PUFAs) such as arachidonic acid (AA). Depending on the position of insertion of oxygen, LOXs are classified into 5-, 8-, 9-, 12- and 15-LOX. Among these, 5-LOX is the most predominant isoform associated with the formation of 5-hydroperoxyeicosatetraenoic acid (5- HpETE), the precursor of non-peptido (LTB4) and peptido (LTC4, LTD4, and LTE4) leukotrienes. LTs are involved in inflammatory and allergic diseases like asthma, ulcerative colitis, rhinitis and also in cancer. Consequently 5-LOX has become target for the development of therapeutic molecules for treatment of various inflammatory disorders. Zileuton is one such inhibitor of 5-LOX approved for the treatment of asthma. In the recent times, computer aided drug design (CADD) strategies have been applied successfully in drug development processes. A comprehensive review on structure based drug design strategies in the development of novel 5-LOX inhibitors is presented in this article. Since the crystal structure of 5-LOX has been recently solved, efforts to develop 5-LOX inhibitors have mostly relied on ligand based rational approaches. The present review provides a comprehensive survey on these strategies in the development of 5-LOX inhibitors.

18 August 2016 in Scientific Reports
Verified
Journal Article
Open access
NKNaresh Kumar
Naresh Kumar
GGGeetika Gupta
Geetika Gupta
KAKotha Anilkumar
Kotha Anilkumar
NFNaireen Fatima
Naireen Fatima
RKRoy Karnati
Roy Karnati
PRPallu Reddanna
Pallu Reddanna
The ratio of ω-6 to ω-3 polyunsaturated fatty acids (PUFAs) appears to be critical in the regulation of various pathophysiological processes and to maintain cellular homeostasis. While a high proportion of dietary intake of ω-6 PUFAs is associated with various inflammatory disorders, higher intake of ω-3 PUFAs is known to offer protection. It is now well established that beneficial effects of ω-3 PUFAs are mediated in part by their oxygenated metabolites mainly via the lipoxygenase (LOX) and cyclooxygenase (COX) pathways. However, the down-stream signaling pathways that are involved in these anti-inflammatory effects of ω-3 PUFAs have not been elucidated. The present study evaluates the effects of 15-LOX metabolites of α-linolenic acid (ALA, ω-3 PUFA) on lipopolysaccharide (LPS) induced inflammation in RAW 264.7 cells and peritoneal macrophages. Further, the effect of these metabolites on the survival of BALB/c mice in LPS mediated septic shock and also polymicrobial sepsis in Cecal Ligation and Puncture (CLP) mouse model was studied. These studies reveal the anti-inflammatory effects of 13-(S)-hydroperoxyoctadecatrienoic acid [13-(S)-HPOTrE] and 13-(S)-hydroxyoctadecatrienoic acid [13-(S)-HOTrE] by inactivating NLRP3 inflammasome complex through the PPAR-γ pathway. Additionally, both metabolites also deactivated autophagy and induced apoptosis. In mediating all these effects 13-(S)-HPOTrE was more potent than 13-(S)-HOTrE.

1 July 2007 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
PDF file
KRKarnati R. Roy
Karnati R. Roy
KAKalle M. Arunasree
Kalle M. Arunasree
NRNishant P. Reddy
Nishant P. Reddy
BDBhavanasi Dheeraj
Bhavanasi Dheeraj
GRGorla Venkateswara Reddy
Gorla Venkateswara Reddy
PRPallu Reddanna
Pallu Reddanna

1 February 2007 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
KSK. V. Sathyasaikumar
K. V. Sathyasaikumar
ISI. Swapna
I. Swapna
PRP. V. B. Reddy
P. V. B. Reddy
CMCh. R. K. Murthy
Ch. R. K. Murthy
AGA. Dutta Gupta
A. Dutta Gupta
PRPallu Reddanna
Pallu Reddanna

15 August 2009 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
KRKarnati R. Roy
Karnati R. Roy
GRGorla V. Reddy
Gorla V. Reddy
LMLeela Maitreyi
Leela Maitreyi
SASmita Agarwal
Smita Agarwal
CAChandrani Achari
Chandrani Achari
PRPallu Reddanna
Pallu Reddanna